| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CR; TC; DAF; CROM |
| Entrez GeneID | 1604 |
| clone | 3F12 |
| WB Predicted band size | 41.4kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD55 (AA: 238-357) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD55抗体的3-4条示例参考文献(内容为虚构，仅作示例参考)：
1. **"CD55/DAF as a therapeutic target in colorectal cancer"**
- 作者：Smith A, et al.
- 摘要：研究揭示了CD55在结直肠癌细胞表面过表达的现象，并证明使用抗CD55单克隆抗体可抑制补体介导的肿瘤免疫逃逸，增强化疗药物的抗肿瘤效果。
2. **"Structural basis of CD55 binding by pathogenic enteroviruses"**
- 作者：Jones B, et al.
- 摘要：通过X射线晶体学解析CD55与肠道病毒结合的分子机制，为开发靶向CD55的中和抗体提供了结构基础。
3. **"Anti-CD55 antibodies ameliorate autoimmune hemolytic anemia in murine models"**
- 作者：Wang C, et al.
- 摘要：在小鼠模型中，靶向CD55的抗体通过调节补体激活通路，显著减轻自身免疫性溶血性贫血症状，提示其潜在临床价值。
4. **"CD55 regulates neutrophil trafficking in inflammatory diseases"**
- 作者：Lee D, et al.
- 摘要：研究发现CD55通过调控补体C3转化酶活性影响中性粒细胞迁移，使用抗CD55抗体可抑制过度炎症反应，为治疗败血症提供新策略。
**备注**：以上为示例性内容，实际文献需通过PubMed、Web of Science等平台检索。建议使用关键词“CD55 antibody”“DAF therapeutic”等结合具体研究方向筛选。
CD55 antibody targets CD55 (Decay-Accelerating Factor, DAF), a glycosylphosphatidylinositol (GPI)-anchored membrane protein that regulates complement activation. CD55 protects host cells from complement-mediated damage by binding to C3 convertases, accelerating their decay, and preventing excessive formation of membrane attack complexes (MACs). It is widely expressed on blood cells, endothelial cells, and epithelial tissues. CD55 antibodies are critical tools in studying complement regulation, immune evasion mechanisms in cancers or pathogens, and autoimmune disorders like paroxysmal nocturnal hemoglobinuria (PNH), where GPI-anchor deficiencies lead to CD55 loss.
These antibodies are used in flow cytometry, immunohistochemistry, and functional assays to assess CD55 expression and its role in disease pathogenesis. Therapeutic CD55-targeting antibodies are explored to modulate complement activity—either blocking CD55 to enhance complement-dependent cytotoxicity in cancer or enhancing its function to suppress inflammation. Additionally, pathogens (e.g., enteroviruses) exploit CD55 as a receptor, making its antibodies valuable in virology research. Commercially available clones (e.g., BRIC216. IH4) recognize specific epitopes within the four short consensus repeat (SCR) domains of CD55. enabling diverse research and diagnostic applications.
×
